SignatureFD
XENE icon

SignatureFD’s Xenon Pharmaceuticals XENE Stock Holding History

SignatureFD’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$27.5K Sell
739
-21
-3% -$1.25K ﹤0.01% 2268
2026
Q2 		$45.9K Buy
760
+207
+37% +$11.5K ﹤0.01% 1931
2026
Q1 		$32.2K Buy
553
+80
+17% +$3.69K ﹤0.01% 1969
2025
Q4 		$21.2K Buy
473
+57
+14% +$2.39K ﹤0.01% 2098
2025
Q3 		$16.7K Sell
416
-245
-37% -$8.63K ﹤0.01% 2195
2025
Q2 		$20.7K Buy
661
+476
+257% +$15.5K ﹤0.01% 2040
2025
Q1 		$6.21K Sell
185
-386
-68% -$14.7K ﹤0.01% 2518
2024
Q4 		$22.4K Buy
571
+334
+141% +$13.8K ﹤0.01% 2012
2024
Q3 		$9.33K Buy
237
+108
+84% +$4.36K ﹤0.01% 2360
2024
Q2 		$5.03K Hold
129
– – ﹤0.01% 2515
2024
Q1 		$5.55K Hold
129
– – ﹤0.01% 2504
2023
Q4 		$5.94K Buy
129
+125
+3,125% +$4.42K ﹤0.01% 2450
2023
Q3 		$137 Sell
4
-9
-69% -$337 ﹤0.01% 3129
2023
Q2 		$501 Sell
13
-20
-61% -$795 ﹤0.01% 3072
2023
Q1 		$1.18K Buy
+33
New +$1.22K ﹤0.01% 2945

Other funds holding XENE

KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Oak Ridge Investments
Oak Ridge Investments Chicago, Illinois $1.68B AUM 48.52% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
J. Safra Sarasin Holding
J. Safra Sarasin Holding $7.05B AUM 26.14% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

SignatureFD's XENE Position: Q3 2026 in Review

SignatureFD reduced its Xenon Pharmaceuticals (XENE) stake by 2.8% in Q3 2026, selling an estimated $1.25K and leaving 739 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2268.

SignatureFD first reported a position in XENE in Q1 2023 and has held it in 15 quarters since. The position peaked at $45.9K in Q2 2026. 47 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • SignatureFD held 739 shares of Xenon Pharmaceuticals worth $27.5K as of Q3 2026.
  • SignatureFD sold 21 Xenon Pharmaceuticals shares in Q3 2026, an estimated $1.25K.
  • Xenon Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2268 holding.
  • SignatureFD first reported a position in Xenon Pharmaceuticals in Q1 2023 and has held it in 15 quarters since.
  • SignatureFD's Xenon Pharmaceuticals position peaked at $45.9K in Q2 2026.
  • 47 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.